BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials. In a new study, a team of researchers reveals how leukemia cells can evade the deadly effects of BRD4 inhibition. Understanding this adaptation process could aid the development of sequential therapies to outsmart resistant leukemias.